Update on recent advances in the management of aspirin exacerbated respiratory disease

Yonsei Medical Journal

Volumn 50, Issue 6, 2009, Pages 744-750

  Palikhe, Nami Shrestha ^a   Kim, Joo Hee ^a   Park, Hae Sim ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Aspirin; Asthma; Eosinophil; Genetic polymorphism; Leukotriene

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BIOLOGICAL MARKER; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; EPSILON OPIATE RECEPTOR; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PRANLUKAST; PROSTAGLANDIN E2; THROMBOXANE A2 RECEPTOR; TRANSCRIPTION FACTOR T BET; ZAFIRLUKAST;

ASTHMA; CELL ACTIVATION; CELL INFILTRATION; CHRONIC RHINITIS; CLINICAL FEATURE; DESENSITIZATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EOSINOPHIL; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MORBIDITY; MORTALITY; NOSE POLYP; PHENOTYPE; POLYPOSIS; RESPIRATORY TRACT DISEASE; REVIEW; RHINOSINUSITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANIMALS; ASTHMA, ASPIRIN-INDUCED; EOSINOPHILS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC;

EID: 74549198663     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.6.744     Document Type: Review

References (59)

1. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirininduced asthma. J Allergy Clin Immunol 2000;106:1201-2.
2. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16:432-6.
3. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22.
4. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002;57:569-74.
5. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L; TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-5.
6. Palikhe NS, Kim SH, Cho BY, Ye YM, Hur GY, Park HS. Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir Med 2008;102:1132-9.
7. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-9.
8. Park HS. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy 1995;25:38-40.
9. Kowalski ML, Ptasinska A, Jedrzejczak M, Bienkiewicz B, Cieslak M, Grzegorczyk J, et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 2005;60:1139-45.
10. Gaber F, Daham K, Higashi A, Higashi N, Gülich A, Delin I, et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008;63:1076-82.
11. Hamad AM, Sutcliffe AM, Knox AJ. Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 2004;64:2417-32.
12. Lee TH, Woszczek G, Farooque SP. Leukotriene (E4): perspective on the forgotten mediator. J Allergy Clin Immunol 2009;124:417-21.
13. Kupczyk M, Antczak A, Kuprys-Lipinska I, Kuna P. Lipoxin A4 generation is decreased in aspirin-sensitive patients in lysineaspirin nasal challenge in vivo model. Allergy 2009;64:1746-52.
14. Hui Y, Funk CD. Cysteinyl leukotriene receptors. Biochem Pharmacol 2002;64:1549-57.
15. Capra V. Molecular and functional aspects of human cysteinyl leukotriene receptors. Pharmacol Res 2004;50:1-11.
16. Ciana P. Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/ cysteinyl-leukotrienes receptor. EMBO J 2006;25:4615-27.
17. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357:1841-54.
18. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-9.
19. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirininduced asthma. Clin Exp Allergy 2001;31:219-25.
20. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaubet A, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999;160:291-6.
21. Morgan T, Bajrovic N, Silar M, Kosnik M, Korosec P. Aspirininduced COX-2 overexpression in monocytes of aspirin-intolerant patients. Int Arch Allergy Immunol 2009;149:378-84.
22. Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirinintolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989;2:127-9.
23. Kowalski ML, Pawliczak R, Wozniak J, Siuda K, Poniatowska M, Iwaszkiewicz J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391-8.
24. Chambers LS, Black JL, Ge Q, Carlin SM, Au WW, Poniris M, et al. PAR-2 activation, PGE2, and COX-2 in human asthmatic and nonasthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003;285:L619-27.
25. Taniguchi M, Higashi N, Ono E, Mita H, Akiyama K. Hyperleukotrieneuria in patients with allergic and inflammatory disease. Allergol Int 2008;57:313-20.
26. Palikhe NS, Kim SH, Cho BY, Ye YM, Choi GS, Park HS. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2009 Oct 1. [Epub ahead of print]
27. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al. J Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-14.
28. Dahlen SH. Novel mechanisms involving new and old eicosanoids in bronchial inflammation. XXVII Congress of the European Academy of Allergy and Clinical Immunology. Warsaw, June 6-10, 2009.
29. Feltenmark S, Gautam N, Brunnström A, Griffiths W, Backman L, Edenius C, et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci U S A 2008;105:680-5.
30. Lee JY, Kim HM, Ye YM, Bahn JW, Suh CH, Nahm D, et al. Role of staphylococcal superantigen-specific IGE antibodies in aspirinintolerant asthma. Allergy Asthma Proc 2006;27:341-6.
31. Suh YJ, Yoon SH, Sampson AP, Kim HJ, Kim SH, Nahm DH, et al. Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma. Clin Exp Allergy 2004;34:1270-5.
32. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.
33. Okada H, Ohnishi T, Hirashima M, Fujita J, Yamaji Y, Takahara J, et al. Anti-asthma effect of an antiviral drug, acyclovir: a clinical case and experimental study. Clin Exp Allergy 1997;27:431-7.
34. Szczeklik A, Schmitz-Schumann M, Nizankowska E, Milewski M, Roehlig F, Virchow C. Altered distribution of IgG subclasses in aspirin-induced asthma: high IgG4, low IgG1. Clin Exp Allergy 1992;22:283-7.
35. Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, et al. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J Allergy Clin Immunol 2004;113:562-4.
36. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C (4) synthase due to overactive transcription of an allelic variant associated with aspirinintolerant asthma. Am J Respir Cell Mol Biol 2000;23:290-6.
37. Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, et al. 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000;106:72-6.
38. Choi JH, Kim SH, Bae JS, Yu HL, Suh CH, Nahm DH, et al. Lack of an association between a newly identified promoter polymorphism (-1702G > A) of the leukotriene C4 synthase gene and aspirin-intolerant asthma in a Korean population. Tohoku J Exp Med 2006;208:49-56.
39. Sayers I, Barton S, Rorke S, Sawyer J, Peng Q, Beghé B, et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase- activating protein (ALOX5AP) genes and asthma susceptibility in a caucasian population. Clin Exp Allergy 2003;33:1103-10.
40. Kim SH, Bae JS, Suh CH, Nahm DH, Holloway JW, Park HS. Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. Allergy 2005;60:760-5.
41. Kim SH, Oh JM, Kim YS, Palmer LJ, Suh CH, Nahm DH, et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy 2006;36:433-9.
42. Kim SH, Ye YM, Hur GY, Lee SK, Sampson AP, Lee HY, et al. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Pharmacogenomics 2007;8:1143-50.
43. Park JS, Chang HS, Park CS, Lee JH, Lee YM, Choi JH, et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics 2005;15:483-92.
44. Kim SH, Bae JS, Holloway JW, Lee JT, Suh CH, Nahm DH, et al. A polymorphism of MS4A2 (- 109T > C) encoding the betachain of the high-affinity immunoglobulin E receptor (FcepsilonR1beta) is associated with a susceptibility to aspirin-intolerant asthma. Clin Exp Allergy 2006;36:877-83.
45. Kim SH, Yang EM, Lee HN, Cho BY, Ye YM, Park HS. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 2009;64:1221-5.
46. Kim SH, Choi JH, Park HS, Holloway JW, Lee SK, Park CS, et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005;35:585-90.
47. Akahoshi M, Obara K, Hirota T, Matsuda A, Hasegawa K, Takahashi N, et al. Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma. Hum Genet 2005;117:16-26.
48. Kim SH, Kim YK, Park HW, Jee YK, Kim SH, Bahn JW, et al. Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma. Pharmacogenet Genomics 2007;17:295-304.
49. Kim TH, Chang HS, Park SM, Nam BY, Park JS, Rhim T, et al. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy 2008;38:1727-37.
50. Kim SH, Jeong HH, Cho BY, Kim M, Lee HY, Lee J, et al. Association of four-locus gene interaction with aspirin-intolerant asthma in Korean asthmatics. J Clin Immunol 2008;28:336-42.
51. Soto-Quiros ME. Practical handling of the asthma based on the control of the disease: Update of GINA guidelines. Anales de Paediatr 2008;68:317-9. http://www.elsevier.es/revistas/ctl-servlet?-f=7064&articuloid=13117700
52. Obase Y, Shimoda T, Tomari SY, Mitsuta K, Kawano T, Matsuse H, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002;121:143-50.
53. Israel E. The protective effects of leukotriene modifiers in aspirininduced asthma. Postgrad Med 2000;108:40-4.
54. Mygind N, Laursen LC, Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy 2000;55:11-5.
55. Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002;32:1491-6.
56. Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004;5:679-86.
57. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirinexacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157-64.
58. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995;96:148-56.
59. Arm JP, Austen KF. Leukotriene receptors and aspirin sensitivity. N Engl J Med 2002;347:1524-6.